BMPR2
ENSG00000204217
Target class
Kinase
Chromosome
2
Approved drugs
2
Clinical candidates (approved and in development)
2
- Approved drugs
- 2
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 2
- Chemical probe available
- Yes
- Target name
- BMPR2
- Gene name
- Bone morphogenetic protein receptor type 2
- Gene symbol
- BMPR2
- Previous gene symbols
- PPH1
- Protein name
- Bone morphogenetic protein receptor type-2 (BMP type-2 receptor) (BMPR-2) (EC 2.7.11.30) (Bone morphogenetic protein receptor type II) (BMP type II receptor) (BMPR-II)
- BRK-3
- T-ALK
- BMPR3
- BMPR-II
- Gene biotype
- Protein coding
- Gene family
- Type 2 receptor serine/threonine kinases
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 45.11
- Tissue specificity (Gini)
- 0.284
- Tissue specificity (tau)
- 0.646
- KEGG gene identifiers
- hsa:659
- Reactome pathways
- R-HSA-201451
- Protein interaction confidence
- 0.905887
- Protein interaction partners
- 53
- End position
- 202567751
- Start position
- 202376327
- Chromosome
- 2
- Strand
- Forward
- Cell membrane
- Single-pass type I membrane protein.
- Nucleoplasm
- Plasma membrane
Publication evidence
- PubMed 25187962
- Tissue specificity (tau)
- 0.645897
- Expression inequality (Gini)
- 0.283905
Expression in transcripts per million
- Lung
- 45.11
- Artery - Aorta
- 35.28
- Artery - Coronary
- 33.87
- Artery - Tibial
- 33.03
- Uterus
- 29.4
Expression in transcripts per million
- Lung45.11
- Artery - Aorta35.28
- Artery - Coronary33.87
- Artery - Tibial33.03
- Uterus29.4
- Cervix - Endocervix28.74
- Cervix - Ectocervix26.66
- Adipose - Subcutaneous25.68
- Adipose - Visceral (Omentum)23.01
- Nerve - Tibial22.63
- Fallopian Tube22.47
- Bladder22.01
- Adrenal Gland21.88
- Cells - Cultured fibroblasts21.8
- Thyroid21.5
- Breast - Mammary Tissue21.19
- Colon - Sigmoid20.34
- Esophagus - Muscularis19.54
- Vagina19.04
- Ovary19.02
- Esophagus - Gastroesophageal Junction18.9
- Brain - Frontal Cortex (BA9)18.48
- Prostate17.52
- Brain - Cerebellar Hemisphere16.54
- Skin - Sun Exposed (Lower leg)14.78
And 29 more, listed on the interactive page.
- GO:0001649
- GO:0001935
- GO:0002063
- GO:0003085
- GO:0007178
- GO:0009267
- GO:0010628
- GO:0010634
- GO:0014916
- GO:0030154
- GO:0030308
- GO:0030501
- GO:0030509
- GO:0042127
- GO:0045669
- GO:0045944
- GO:0048662
- GO:0060391
- GO:0060426
- GO:0071773
- GO:0072577
- GO:1902731
- GO:0005576
- GO:0005886
- GO:0005901
- GO:0005912
- GO:0005515
- GO:0016362
- GO:0036122
- GO:0045296
- GO:1990782
Related records
Trials (116)
- A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses
- A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis
- A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis
- A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China
- A Phase 2/3 Multicenter, Controlled Trial Of rhBMP-2/CPM In Tibial Fractures
- A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
- A Real-world Study of Deucravacitinib in the Treatment of Moderate to Severe Plaque Psoriasis With Eczematous Features
- A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)
- A Study Comparing the Effects of Famotidine Pretreatment and of Food on the Relative Bioavailability of BMS-986165 in Healthy Volunteers
- A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis
- A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis
- A Study Evaluating Deucravacitinib Concentrations in the Breast Milk and Plasma of Healthy Lactating Female Participants
- A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer
- A Study of Deucravacitinib to Treat LPP and FFA
- A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
- A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
- A Study of rhBMP-2/CPM in Closed Fractures of the Humerus
- A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)
- A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis
- A Study on the Safety of Deucravacitinib Exposure in Pregnant Women and Their Offspring
Drugs (3)
- Deucravacitinib
- Dibotermin alfa Bone morphogenetic protein receptor type-2 agonist
- Eptotermin alfa Bone morphogenetic protein receptor type-2 agonist